BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Credentis AG Obtains ISO 9001 & ISO 13485 Certificate


6/27/2011 11:22:50 AM

June 27, 2011 -- credentis ag is proud to announce the successful completion of the ISO 9001/13485 certification of the company. The certificates were issued by the Swiss Association for Quality and Management Systems (SQS).

The compliance with ISO 13485 is an important milestone in the regulatory process. As a next step, credentis aims at obtaining market approval for its first product before the end of the year.

About P11-4

The first product of credentis that will be submitted for market approval (CE-label) will be the self- assembling peptide P11-4.

P11-4 provides dentists with a novel technology to regenerate rather than repair carious and other tooth lesions. Applied to a small lesion, P11-4 forms a scaffold of small fibres within the lesion around which new enamel or dentin can form and grow. Ideally, within eight days the lesion will regenerate without the use of burr or filler.

The results from the ongoing study at Leeds are very encouraging: “We want to develop not only a product, but a new approach to caries. This will revolutionize dental care”, explains Dominik Lysek. The ultimate goal is to prevent caries by frequent recalls to dentists and dental hygienists. Within clinical studies credentis continues to optimize and test the application and the range of indications of P11-4.

About credentis ag

credentis has its headquarters in the Technopark Aargau Switzerland, Windisch; it has already won the support of Genilem and presented itself successfully at various events including the Argovian and Swiss Equity Fairs and was one of Swiss Venture Leaders 2011.

CEO Dominik Lysek and CTO Michael Hug have expert knowledge in medicinal technology and a strong network in the dental industry. Dr. Werner Berner (member of the board) and Dr. Erich Platzer (chairman of the board) perfectly complement the know-how of the management and contribute to the success of the young company with their expert industry knowledge.

Contact: Dr. Dominik Lysek, CEO, tel +41 56 560 2040; dl@credentis.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES